These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34956179)

  • 1. KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Zhang T; Shen P; Duan C; Gao L
    Front Immunol; 2021; 12():745233. PubMed ID: 34956179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality.
    Rai M; Parthasarathi A; Beeraka NM; Kaleem Ullah M; Malamardi S; Padukudru S; Siddaiah JB; Uthaiah CA; Vishwanath P; Chaya SK; Ramaswamy S; Upadhyay S; Ganguly K; Mahesh PA
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
    Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
    Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
    d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
    Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
    Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
    PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
    Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
    Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
    Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
    Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.
    Zhang H; Chen L; Wu L; Huang J; Li H; Wang X; Weng H
    Medicine (Baltimore); 2020 Apr; 99(16):e19493. PubMed ID: 32311922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
    Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
    Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.
    d'Alessandro M; Conticini E; Bergantini L; Mazzei MA; Bellisai F; Selvi E; Cameli P; Frediani B; Bargagli E
    Tissue Cell; 2024 Oct; 90():102516. PubMed ID: 39137538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
    Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
    Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease.
    Tanaka N; Nishimura K; Waki D; Kadoba K; Murabe H; Yokota T
    Mod Rheumatol; 2021 Nov; 31(6):1100-1106. PubMed ID: 33496209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
    Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
    Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer.
    Park HK; Yoon CS; Na YO; Lee JK; Oh HJ; Park HY; Kho BG; Kim TO; Shin HJ; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Park CK
    Sci Rep; 2023 Oct; 13(1):18126. PubMed ID: 37872370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
    Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
    Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
    Ma H; Lu J; Song Y; Wang H; Yin S
    BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum YKL-40 and Serum Krebs von den Lungen-6 as Potential Predictive Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Liang B; Zhang Y; Ke D; Yan R; Jiang MN; Li L; Zhang LX; Zhao XG; Yuan GP; Xu B; Liu XM
    Immunol Invest; 2024 Aug; 53(6):989-1000. PubMed ID: 38900045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.